Aldeyra Therapeutics, Inc.

This early-phase study tested an experimental drug called ADX-2191 in 8 adults with retinitis pigmentosa caused by a specific gene mutation (rhodopsin). Participants received multiple injections into the worse-seeing eye to evaluate safety and any changes in vision. The goal was …

This early-phase study tested the safety of a new drug, ADX-629, in 4 adults with moderate alcohol-related hepatitis. Participants took the drug by mouth and agreed to stop drinking alcohol during the trial. The main goal was to see if the drug caused any side effects, not to cur…

This study tested an eye drop called reproxalap (0.25%) against a placebo in 116 adults with dry eye disease. The goal was to see if it reduces eye discomfort over 100 minutes in a dry environment. Participants used the drops and rated their discomfort on a scale from 0 to 100.

This study tested an eye drop called reproxalap in 421 adults with dry eye disease. Participants used the drops or a placebo for up to 6 weeks. The main goal was to see if the drops reduce eye discomfort better than placebo.

This study tested the safety of an eye drop called reproxalap in 757 adults with dry eye disease. Participants used the drops for up to 12 months to check for serious side effects like vision changes or eye pressure increases. The goal was to see if the treatment is safe, not to …